No Data
After Leaping 35% Xiangyu Medical Co.,Ltd (SHSE:688626) Shares Are Not Flying Under The Radar
Xiangyu Medical 2024 Annual Results Report Announcement
The delay in hospital bidding combined with an increase in research and development costs has led to a decline of over fifty percent in Xiangyu Medical's net profit in 2024.
① Xiangyu Medical expects that by 2025 all expenses can be stably controlled, and the company's Net income will return to a growth trend. Mental health products have already met the marketable conditions outside hospitals, and proactive training products are expected to obtain registration certificates by 2025; ② In January 2025, Xiangyu Medical added two new training products that received CE certification, and it is expected that two therapeutic products will obtain certification by mid-2025.
Xiangyu Medical (688626.SH): In the year 2024, the net income is 0.103 billion yuan, a decrease of 54.44% year-on-year.
On February 21, Gelonghui reported that Xiangyu Medical (688626.SH) announced its performance quick report for 2024. During this reporting period, the company achieved total revenue of 0.743 billion yuan, a year-on-year decrease of 0.17%; the net income attributable to the parent company's owners was 0.103 billion yuan, a year-on-year decrease of 54.44%; and the net income attributable to the parent company's owners after deducting non-recurring gains and losses was 90.4665 million yuan, a year-on-year decrease of 55.66%. During the reporting period, facing opportunities and challenges, the company adhered to technological innovation, continuously improved management levels and operational capabilities, and its revenue remained basically flat compared to the previous year. At the same time, the company
Xiangyu Medical (688626.SH): Suzhou Jifeng and Fuzhou Jifeng have collectively reduced their Shareholding by 0.4 million shares of the company.
On February 17, 2025, Xiangyu Medical (688626.SH) announced that it received a notice from shareholders Suzhou Jifeng, Jiaxing Jifeng No. 1, and Fuzhou Jifeng regarding the expiry of their shareholding plan and the results of the shareholding reduction. As of February 17, 2025, Suzhou Jifeng and Fuzhou Jifeng have reduced the company's shares by a total of 400,200 shares through centralized competitive trading, accounting for 0.250125% of the company's total equity. The shareholding reduction plan has ended.
These 4 Measures Indicate That Xiangyu MedicalLtd (SHSE:688626) Is Using Debt Extensively
Investors Aren't Buying Xiangyu Medical Co.,Ltd's (SHSE:688626) Earnings
